Hogan Lovells appoints Gary Veron
Gary Veron has joined Hogan Lovells’ government regulatory practice as a partner in the Washington, DC, office. He joins from Sidley Austin, where he served as counsel in the food and drug practice.
Veron focuses his practice on food and drug law with an emphasis on the intersection of regulatory law and intellectual property law for pharmaceutical and biotechnology products. He represents pharmaceutical, biotechnology and medical device companies on a range of US Food and Drug Administration (FDA) regulatory and enforcement matters.
His practice over the past 10 years has focused primarily on the Hatch-Waxman Act and lifecycle management issues. He is a frequent advocate before the FDA on behalf of manufacturers of pioneer and brand-name pharmaceuticals. In a recent complex petition matter, Veron won a significant ruling, limiting the ability of generic drug applicants to avoid a pioneer company’s exclusivity rights.
Veron is a registered patent attorney and before practising law served as a technology development specialist in the US National Institutes of Health (NIH). He also served as legislative counsel to the Maryland General Assembly.
He holds a JD from the University of Virginia School of Law and a BS in biology from Virginia Polytechnic Institute.
News from Hogan Lovells
News from The Lawyer
Briefings from Hogan Lovells
The decision of the US Court of Appeals has raised questions about how issuers should present their disclosures on conflict minerals under Exchange Act Rule 13p-1 and Form SD.
An interesting judgment was delivered by the Honourable J Majiki on 19 November 2013 in the Eastern Cape High Court, Port Elizabeth.
Analysis from The Lawyer
As international firms question their future in these small, closely linked markets, local lawyers too are eyeing the business environment with caution
Beyond the headline infrastructure projects, UK construction work is still recovering from the clobbering it took during the slump